Latuda
28.9 هزار بار بازدید -
5 سال پیش
-
Latuda belongs to the atypical
Latuda belongs to the atypical antipsychotic family of drugs meant to treat schizophrenia and bipolar disease. Unlike other related drugs, Latuda acts against the depression of bipolar disease and is not indicated for the manic stages. Latuda may be prescribed to individuals as young as 10 years of age, however diagnosis in the pediatric population remains somewhat controversial.
Unfortunately Latuda offers only some degree of improvement rather than cure. In some studies Latuda fails to provide statistically significant evidence of improvement. When it does offer relief, a common scenario is only reducing a person's status from markedly ill to moderately ill.
Evidence for Latuda stems from studies the company conducted throughout the world. To some extent this detracts from the believability of the data since it poses almost insurmountable difficulties in monitoring and compliance. Latuda was evaluated in Ukraine, India, Romania, Russia, Bulgaria, Serbia, Argentina, Colombia, South Africa and Peru among others. With international cultural and social differences, studies involving a more homogenous population would be preferable. Finding 500 patients in America, Canada, Australia or England with such common conditions ought to be an easy task.
As with most patent protected antipsychotics the cash price at the pharmacy remains out of control. At Costco the drug sells for in excess of $45 a pill or $1414 a month; at Walgreens it is considerably more. Latuda's manufacturer's apparent target is the insurance company. It offers a discount card allowing the consumer to pay less than $10 a month as long as Medicare, Medicaid and Tricare are not involved. The company negotiates some discount with private insurers but not the government. Generic forms of Seroquel, Abilify, Resperdal and Zyprexa are available for a monthly cost of less than $20.
Unfortunately Latuda offers only some degree of improvement rather than cure. In some studies Latuda fails to provide statistically significant evidence of improvement. When it does offer relief, a common scenario is only reducing a person's status from markedly ill to moderately ill.
Evidence for Latuda stems from studies the company conducted throughout the world. To some extent this detracts from the believability of the data since it poses almost insurmountable difficulties in monitoring and compliance. Latuda was evaluated in Ukraine, India, Romania, Russia, Bulgaria, Serbia, Argentina, Colombia, South Africa and Peru among others. With international cultural and social differences, studies involving a more homogenous population would be preferable. Finding 500 patients in America, Canada, Australia or England with such common conditions ought to be an easy task.
As with most patent protected antipsychotics the cash price at the pharmacy remains out of control. At Costco the drug sells for in excess of $45 a pill or $1414 a month; at Walgreens it is considerably more. Latuda's manufacturer's apparent target is the insurance company. It offers a discount card allowing the consumer to pay less than $10 a month as long as Medicare, Medicaid and Tricare are not involved. The company negotiates some discount with private insurers but not the government. Generic forms of Seroquel, Abilify, Resperdal and Zyprexa are available for a monthly cost of less than $20.
5 سال پیش
در تاریخ 1398/11/14 منتشر شده
است.
28,968
بـار بازدید شده